Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters11-15

* Salarius Pharmaceuticals Inc reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The lone analyst forecast for the quarter was for a loss of $2.40 per share.

* Reported revenue was zero; analysts expected zero.

* Salarius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 76 cents.

* The company reported a quarterly loss of $972.12 thousand.

* Salarius Pharmaceuticals Inc shares had fallen by 4.2% this quarter and lost 73.5% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

This summary was machine generated from LSEG data November 15 at 02:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -2.40 -0.76 Beat

-2.37

Mar. 31 2024 -53.60 -3.28 Beat

-1.79

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483371843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483371843","market":"us","top_or_hot":-1,"title":"Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a>    reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20.  The lone analyst forecast for the quarter was for a loss of $2.40 per share. </p><p>   * Reported revenue was zero; analysts expected zero. </p><p>   * Salarius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 76 cents.</p><p>   * The company reported a quarterly loss of $972.12 thousand.</p><p>   * Salarius Pharmaceuticals Inc shares had fallen by 4.2% this quarter and lost 73.5% so far this year.</p><p>FORECAST CHANGES</p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\" </p><p>   * The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"hold\"</p><p>This summary was machine generated from LSEG data November 15 at 02:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Sep. 30 2024      -2.40          -0.76          Beat</p><p>                                 -2.37          </p><p>Mar. 31 2024      -53.60         -3.28          Beat</p><p>                                 -1.79          </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Salarius Pharmaceuticals Inc    reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLRX","symbol_name":"Salarius Pharmaceuticals Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2483371843","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483371843","pubTimestamp":1731679484,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Salarius Pharmaceuticals Inc    reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SLRX":"Salarius Pharmaceuticals Inc"},"translate_title":"Salarius Pharmaceuticals Inc报告截至9月30日的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRX":1},"content_text":"* Salarius Pharmaceuticals Inc    reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20.  The lone analyst forecast for the quarter was for a loss of $2.40 per share.    * Reported revenue was zero; analysts expected zero.    * Salarius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 76 cents.   * The company reported a quarterly loss of $972.12 thousand.   * Salarius Pharmaceuticals Inc shares had fallen by 4.2% this quarter and lost 73.5% so far this year.FORECAST CHANGES   * The mean earnings estimate of analysts was unchanged in the last three months.    * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"    * The average consensus recommendation for the biotechnology & medical research peer group is also \"hold\"This summary was machine generated from LSEG data November 15 at 02:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDSep. 30 2024      -2.40          -0.76          Beat                                 -2.37          Mar. 31 2024      -53.60         -3.28          Beat                                 -1.79","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483371843"}